|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of 8 male and 2 female NaPB-induced liver tumour samples (comprising 2 adenomas, 6 carcinomas and 2 samples containing separate adenomas and carcinomas) revealed truncated β-catenin forms in just 4 male liver tumour samples, with the presence of the truncated β-catenin forms being confirmed by β-catenin exon 1-3 mutation analysis.
|
31836555 |
2020 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Background: We evaluated the immunoexpression of LGR4 and β-catenin in primary gastric carcinomas, lymph
|
30803215 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HNF1A mutations in carcinomas were associated with negative viral hepatitis status (p = .004), mutually exclusive with catenin beta-1 (CTNNB1) hotspot mutations, and trended to occur more in females (p = .06) and without cirrhosis (p = .03).
|
30121369 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, nuclear expression of SIRT6 (104 ovarian carcinomas; <i>P</i> = 0.010, 63 high-grade serous carcinomas; <i>P</i> = 0.040), and activated β-catenin (104 ovarian carcinomas; <i>P</i> = 0.013, 63 high-grade serous carcinomas; <i>P</i> = 0.005) were independent indicators of shorter overall survival of ovarian carcinoma patients in multivariate analysis.
|
30524965 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Mucin-poor types were significantly associated with high histologic grade dysplasias/carcinomas and high nuclear β-catenin labeling indices.
|
29975247 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
All carcinomas were negative for β-catenin and maintained nuclear SMARCB1 (INI1) and ARID1A expression.
|
29133142 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We applied genotyping (Sanger, qPCR, 101-gene panel NGS), mRNA relative quantification methods, and β-catenin immunohistochemistry in 84 FFPE BTC (55 gallbladder [GBC], 14 intrahepatic [ICC], 15 extrahepatic [ECC] carcinomas).
|
29416916 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As β-catenin is mutated in a wide variety of tumors, including up to 10% of all sporadic colon carcinomas and 20% of hepatocellular carcinomas, it has been considered a promising target for therapeutic interventions.
|
28107588 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We found high epithelial marker expressions (CK8/18, E-cadherin, membranous β-catenin) only in a distinct variety of carcinomas.
|
27729431 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant β-catenin expression in urothelial carcinomas in blackfoot disease-endemic areas.
|
28088268 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Previous studies have shown that gain-of-function mutations in the CTNNB1 gene contribute to the occurrence and development of a variety of carcinomas in humans.
|
28514307 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Alterations of the β-catenin (CTNN1B, ZNFR3) or TP53 pathways are found in carcinomas.
|
26038203 |
2015 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Forty-one (93%) of these carcinomas displayed membranous β-catenin staining only, compared with 28 (64%) site-matched MSS tumors with abnormal nuclear β-catenin staining.
|
25602793 |
2015 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutations in the Wnt pathway components APC and CTNNB1 were more common among gastric carcinomas (16% vs. 3%, p = 0.006), and gastric carcinomas were more likely to have ≥3 driver mutations detected (11% vs. 2%, p = 0.044).
|
25656989 |
2015 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
|
26276776 |
2015 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas.
|
24158497 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All carcinomas exhibited significant alterations of beta-catenin expression (P < 0.05).
|
24511551 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, in renal carcinoma, we demonstrate that (i) MUC1 and SNAIL were overexpressed in human sarcomatoid carcinomas, (ii) SNAIL increased indirectly MUC1 expression, (iii) MUC1 overexpression induced EMT, (iv) MUC1 C-terminal domain (MUC1-C) and β-catenin increased SNAIL transcriptional activity by interaction with its promoter and (v) blocking MUC1-C nuclear localization decreased Wnt/β-catenin signaling pathway activation and SNAIL expression.
|
24384091 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SPRY2 protein expression correlated with nuclear β-catenin and FOXO3a colocalization in human colon carcinomas.
|
23624922 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequent observation of constitutive activation of Wnt signaling due to loss-of-function mutations in the tumor suppressor gene APC or gain-of-function mutation in β-catenin in both adenomas and carcinomas, suggests perhaps that the Wnt pathway serves an early or initiating insult in the oncogenic process.
|
22266195 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that D3 is a direct transcriptional target of the β-catenin/TCF complex; its expression was higher in human intestinal adenomas and carcinomas than in healthy intestinal tissue.
|
22771508 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In MLH1-positive cases, combined high scores of CD133 and β-catenin were associated with a very high rate of distant metastases (94.4%), whereas the risk was intermediate for carcinomas with either low CD133 and/or low β-catenin expression (P = 0.0007).
|
22276605 |
2012 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In high-grade dysplastic lesions that are caused by high-risk HPVs (HR-HPV), β-catenin is often located in the cell nucleus, which suggests that Wnt pathway may be involved in the development of HPV-related carcinomas.
|
22160870 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subgroup analysis of non-lobular cancers or non-lobular grade 3 carcinomas revealed that lack/reduction of β-catenin membranous expression and/or nuclear accumulation were significantly associated with oestrogen receptor negativity, absence of HER2 gene amplification and overexpression, lack/reduction of E-cadherin expression and tumours of triple-negative and basal-like phenotype.
|
21076461 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In our study, we examined the expression pattern of claudins, beta-catenin and E-cadherin in invasive ductal (IDCs) and lobular (ILCs) carcinomas and their corresponding lymph node metastases (LNMs).
|
20963473 |
2011 |